GlaxoSmithKline
United States
3271 articles about GlaxoSmithKline
-
Preliminary trial results show the GSK five-in-one meningitis vaccine is immunologically effective against the most common strains, as the FDA decision date for Pfizer’s candidate looms. -
SCYNEXIS Announces First Quarter 2023 Financial Results and Provides Corporate Update
5/11/2023
SCYNEXIS, Inc. announced financial results for the first quarter ended March 31, 2023.
-
CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK
5/8/2023
CureVac N.V. today announced that the first participant was dosed in the Phase 1 part of a combined Phase 1/2 study of multivalent, modified mRNA seasonal flu vaccine candidates, developed in collaboration with GSK.
-
As the COVID-19 market dries up, Moderna looks to FDA approval of its other vaccines including a 2024 commercial launch of its investigational RSV vaccine for older adults. -
The regulatory decision marks a turning point in the RSV race in what’s expected to be a competitive space. -
Phase III data for Pfizer's respiratory syncytial virus vaccine candidate showed high levels of protection for older adults and infants. -
Merck’s Keytruda appeared to outperform GSK’s Jemperli in a key endometrial cancer patient subgroup, based on late-stage data revealed Monday during the Society of Gynecologic Oncology 2023 Annual Meeting. -
As demand for biotech talent increases, the need to offer competitive pay to the average employee puts financial pressure on companies to increase CEO pay as well. -
The FDA is expected to cap off February with a trio of verdicts, including one for a heart failure treatment and another potential first approval for a rare, neurodegenerative disease. -
The COVID-19 research collaboration between Vir Biotechnology and GSK has largely come to an end, as Vir announced Monday it would be going it alone or with other partners. -
US FDA grants regular approval for Jemperli for the treatment of patients with recurrent or advanced mismatch repair-deficient endometrial cancer
2/10/2023
GSK plc reports that the US Food and Drug Administration granted full approval for Jemperli for the treatment of adult patients with mismatch repair-deficient recurrent or advanced endometrial cancer, as determined by a US FDA-approved test, that has progressed on or following a prior platinum-containing regimen in any setting and are not candidates for curative surgery or radiation.
-
Wednesday, the FDA approved GSK’s daprodustat, now to be marketed as Jesduvroq, for the treatment of anemia due to chronic kidney disease in adult patients. -
GSK has dropped two assets, an investigational celiac disease therapeutic and a Staphylococcus aureus vaccine hopeful, from its pipeline.
-
WuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers
1/5/2023
WuXi Biologics announced a license agreement with GSK plc under which GSK will have exclusive licenses for up to four bi- & multi-specific TCE antibodies developed using WuXi Biologics' proprietary technology platforms.
-
Mantra Pharma in Action - Mantra Pharma Introduces the First Generic Alternative to CLAVULIN® (GSK) in Canada
1/3/2023
Following an increase in cases of respiratory viruses, Canada is currently experiencing supply issues for an oral antibiotic for children, the CLAVULIN® from GSK.
-
2022's Top Clinical Advancements: See Pivotal Data in NASH, Alzheimer’s, Sickle Cell Disease
12/23/2022
2022 featured pivotal data that could change the landscape in non-alcoholic steatohepatitis, Alzheimer’s disease, sickle cell disease and many more indications. -
GSK bolstered its position in the oligonucleotide therapeutics space through a four-year collaboration with Wave Life Sciences valued at up to $3.3 billion.
-
New data at ASH underscore the potential for durable, clinically important responses with momelotinib for myelofibrosis patients
12/11/2022
GSK plc announced new 48-week data from the MOMENTUM phase III trial that showed a majority of patients treated with investigational momelotinib maintained their responses across key clinical measures including Total Symptom Score, Transfusion Independence rate, and Splenic Response Rate in myelofibrosis patients previously treated with an approved Janus kinase inhibitor.
-
GSK intends to file for approval of Jemperli in endometrial cancer after the checkpoint inhibitor met its primary endpoint in the Phase III RUBY trial.
-
Following a request from the FDA, GSK is withdrawing its multiple myeloma drug Blenrep from the U.S. market while continuing to push other combination trial programs.